Announcements Trials

Browse Landscape

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Papillomavirus Infections 9 Uterine Cervical Neoplasms 4 Neuroendocrine Tumors 4 Autoimmune Diseases 3 Prostatic Neoplasms 2 Neoplasms 2 Abortion, Spontaneous 2 Recurrence 1 Ovarian Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Neuroblastoma 1 Neoplastic Cells, Circulating 1 Neoplasm Metastasis 1 Myasthenia Gravis 1 Lymphohistiocytosis, Hemophagocytic 1 Lung Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1

Interventions

Carboplatin 367 Pemetrexed 308 pembrolizumab 302 Cisplatin 242 Paclitaxel 230 Docetaxel 199 Gemcitabine 130 Nivolumab 121 Erlotinib Hydrochloride 114 Bevacizumab 85 osimertinib 78 atezolizumab 65 durvalumab 58 Cetuximab 57 130-nm albumin-bound paclitaxel 56 Gefitinib 52 Ipilimumab 46 Afatinib 38 Drug Therapy 33 Cyclophosphamide 30 Crizotinib 30 Albumin-Bound Paclitaxel 30 Vinorelbine 28 cemiplimab 26 tislelizumab 25 avelumab 23 icotinib 22 Radiotherapy 22 capmatinib 21 Oxaliplatin 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Carcinoma, Non-Small-Cell Lung × Data Collection × Clear all

NCT01772225 2014-03-31

LuCaBIS

GlaxoSmithKline

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡